NO943521L - Anvendelse av et pyrrolidinacetamidderivat for fremstilling av et terapeutikum - Google Patents

Anvendelse av et pyrrolidinacetamidderivat for fremstilling av et terapeutikum

Info

Publication number
NO943521L
NO943521L NO943521A NO943521A NO943521L NO 943521 L NO943521 L NO 943521L NO 943521 A NO943521 A NO 943521A NO 943521 A NO943521 A NO 943521A NO 943521 L NO943521 L NO 943521L
Authority
NO
Norway
Prior art keywords
preparation
therapeutic agent
acetamide derivative
pyrrolidine acetamide
pyrrolidine
Prior art date
Application number
NO943521A
Other languages
English (en)
Norwegian (no)
Other versions
NO943521D0 (no
Inventor
Ernst Wulfert
Jean Gobert
Alma Gower
Eric Cossement
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of NO943521D0 publication Critical patent/NO943521D0/no
Publication of NO943521L publication Critical patent/NO943521L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
NO943521A 1993-09-24 1994-09-22 Anvendelse av et pyrrolidinacetamidderivat for fremstilling av et terapeutikum NO943521L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939319732A GB9319732D0 (en) 1993-09-24 1993-09-24 Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety

Publications (2)

Publication Number Publication Date
NO943521D0 NO943521D0 (no) 1994-09-22
NO943521L true NO943521L (no) 1995-03-27

Family

ID=10742476

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943521A NO943521L (no) 1993-09-24 1994-09-22 Anvendelse av et pyrrolidinacetamidderivat for fremstilling av et terapeutikum

Country Status (17)

Country Link
US (1) US5447952A (enExample)
EP (1) EP0645139B1 (enExample)
JP (1) JP3688735B2 (enExample)
KR (1) KR950007848A (enExample)
AT (1) ATE191849T1 (enExample)
AU (1) AU672334B2 (enExample)
CA (1) CA2132509A1 (enExample)
DE (1) DE69424009T2 (enExample)
ES (1) ES2145818T3 (enExample)
GB (1) GB9319732D0 (enExample)
HU (1) HU217124B (enExample)
NO (1) NO943521L (enExample)
NZ (1) NZ264506A (enExample)
RU (1) RU2142274C1 (enExample)
SG (1) SG86284A1 (enExample)
TW (1) TW283642B (enExample)
ZA (1) ZA947444B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525347A (en) * 1995-01-31 1996-06-11 Medical University Of South Carolina Composition and methods for treating performance anxiety
CA2392879C (en) 1999-12-01 2005-03-29 Ucb, S.A. A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
ES2317452T3 (es) * 2006-01-24 2009-04-16 Teva Pharmaceutical Industries Limited Formulaciones de levetiracetam y procedimientos para su preparacion.
EA015256B1 (ru) * 2006-03-15 2011-06-30 Актелион Фармасьютикалз Лтд. Производные тетрагидроизохинолина для повышения функции памяти
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
US8106215B2 (en) * 2007-07-03 2012-01-31 Actelion Pharmaceuticals Ltd. 3-aza-bicyclo[3.3.0]octane compounds
KR20100046047A (ko) * 2007-07-27 2010-05-04 액테리온 파마슈티칼 리미티드 2-아자-비시클로[3.3.0]옥탄 유도체
EP2346500B1 (en) 2008-10-16 2017-05-17 The Johns Hopkins University Methods and compositions for improving cognitive function
US8191547B2 (en) * 2008-10-23 2012-06-05 S-2Tech Llc Portable solar-heating system having an inflatable solar collector
US20100172979A1 (en) * 2008-12-24 2010-07-08 Zhongshui Yu Controlled-release formulations
US20100159009A1 (en) * 2008-12-24 2010-06-24 Zhongshui Yu Controlled-release formulations
EP2533645B1 (en) * 2010-02-09 2016-07-27 The Johns Hopkins University Methods and compositions for improving cognitive function
EP2672822A4 (en) * 2011-02-09 2014-08-27 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTIONS
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
EA034167B8 (ru) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Фармацевтические композиции леветирацетама пролонгированного высвобождения
JP2022510363A (ja) * 2018-12-04 2022-01-26 メティス ファーマシューティカルズ アクチェンゲゼルシャフト （ｒ）－２－（２－オキソピロリジン－１－イル）ブタンアミドと（ｓ）－２－（２－オキソピロリジン－１－イル）ブタンアミドを非ラセミ比で含む相乗的組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1414845A1 (ru) * 1984-03-23 1988-08-07 Всесоюзный Научно-Исследовательский Химико-Фармацевтический Институт Им.С.Орджоникидзе 1-Тиокарбамоилметилпирролидин-2-тион,обладающий ноотропной активностью, и способ его получени
GB8412357D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
SU1320707A1 (ru) * 1985-01-24 1987-06-30 Ивано-Франковский Институт Нефти И Газа Способ определени износостойкости материалов ма тниковым склерометром
GB8827389D0 (en) 1988-11-23 1988-12-29 Ucb Sa Process for preparation of(s)alpha-ethyl-2-oxo-1-pyrrolidineacetamide
EP0408782A1 (en) * 1989-07-18 1991-01-23 Nauchnoissledovatelski Chimikopharmatzevtichen Institut Antihypoxic agent
CA2048003A1 (en) * 1990-08-21 1992-02-22 Serge Burner Tricyclic pyridone derivatives

Also Published As

Publication number Publication date
HUT68299A (en) 1995-06-28
NO943521D0 (no) 1994-09-22
NZ264506A (en) 1997-09-22
DE69424009D1 (de) 2000-05-25
ATE191849T1 (de) 2000-05-15
EP0645139A1 (fr) 1995-03-29
AU7416994A (en) 1995-04-06
CA2132509A1 (en) 1995-03-25
US5447952A (en) 1995-09-05
HU217124B (hu) 1999-11-29
JPH07149639A (ja) 1995-06-13
DE69424009T2 (de) 2000-09-14
KR950007848A (ko) 1995-04-15
ZA947444B (en) 1995-05-11
GB9319732D0 (en) 1993-11-10
TW283642B (enExample) 1996-08-21
EP0645139B1 (fr) 2000-04-19
ES2145818T3 (es) 2000-07-16
SG86284A1 (en) 2002-02-19
AU672334B2 (en) 1996-09-26
RU2142274C1 (ru) 1999-12-10
JP3688735B2 (ja) 2005-08-31

Similar Documents

Publication Publication Date Title
NO943521D0 (no) Anvendelse av et pyrrolidinacetamidderivat for fremstilling av et terapeutikum
ATE170510T1 (de) 3-(hydroxybenzylidenyl)-indolin-2-one und diese enthaltende arzneimittel
DE69201956D1 (de) Pyrrolidin- und thiazolidinderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
DK0613894T3 (da) N-Heteroaryl-N'-phenylurinstofderivater, fremstilling og anvendelse deraf
NO933200L (no) Substituerte cykloheksanderivater, fremgangsmåte til fremstilling derav og anvendelsen av forbindelsene til behandling av sykdommer
NO902800L (no) Fremgangsmaate for fremstilling av 11beta-aryl-4-oestrener.
ES2103440T3 (es) Nuevas amidas y sulfonamidas naftalenicas, procedimiento de preparacion y composiciones farmaceuticas que las contienen.
DK0617959T3 (da) Lægemiddel til behandling af hudsygdomme
FI923662A0 (fi) Terapeutiska medel.
ES2123728T3 (es) Derivados de pirrolo-pirazina de actividad 5-ht3.
DK0454429T3 (da) Anvendelse af 15-dehydroxy-16-oxoprostaglandinderivater til behandling af allergiske sygdomme
ZA88639B (en) Substituted 3-phenyl-7h-thiazolo(3,2-b)(1,2,4)triazin-7-ones,a process for the preparation thereof,medicaments containing same and the use thereof,and also some intermediates formed in the preparation of the compounds mentioned
ES2076054T3 (es) Nuevas amino-alquil-cromonas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
GR3003065T3 (en) Use of n-((1-ethyl-2-pyrrolidinyl)methyl)-methoxy-5-sulfamoyl benzamide in the treatment of sterility
NO172339C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktiv (+)1-((3,4,5-trimetoksy)benzyloksymetyl)-1-fenyl-n,n-dimetyl-n-propylamin
NO172120C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive isoxazoler
DK0488044T3 (da) En imidazobenzodiazepin til behandling af søvnforstyrrelser
ZA917273B (en) Use of n-(1-hexahydroazepinylalkyl)acetamides in the preparation of medicaments for the treatment of cholinergic transmission disorders
GR3015592T3 (en) Pharmaceuticals containing substituted cyclohex-2-en-1-yl-amine derivatives and their use in combatting diseases.
GR3037039T3 (en) Use of trimetazidine for the preparation of medicaments for the treatment of troubles due to the therapeutical use of immunosuppressants.
FI882388A0 (fi) 4-substituerad 10-cyanmetylenpyrrolo /4,3-e/benzoazepin.
NO156410C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 6aaa-methylprednisolonderivater.
DK0671910T3 (da) Anvendelse af adamantanderivater til fremstilling af et lægemiddel til behandling af glaucoma
FR2742337B1 (fr) Application du 3-alpha-hydroxy-5-alpha-androsta-16-ene a titre de medicaments
IT1270689B (it) "derivati benzossazinonici e benzotiazinonici e loro uso terapeutico"